Research Topics
| Emmanuelle Charafe JauffretSummaryAffiliation: Institut Paoli-Calmettes Country: France Publications
| Collaborators
|
Detail Information
Publications
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialJocelyne Jacquemier
Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
Breast Cancer Res 13:R109. 2011..We searched for prognostic and predictive markers for docetaxel's benefit...- Genome profiling of ERBB2-amplified breast cancersFabrice Sircoulomb
Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
BMC Cancer 10:539. 2010..They are associated with a poor prognosis but can benefit from targeted therapy. A better knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and design new therapeutic strategies... 
Nectin-4 is a new histological and serological tumor associated marker for breast cancerStéphanie Fabre-Lafay
INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
BMC Cancer 7:73. 2007..Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma...- Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherinAzza Ben Hamida
Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
BMC Cancer 8:28. 2008..The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC... - Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancersAnne Letessier
Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
BMC Cancer 6:245. 2006..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers... 
Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphomaEmmanuelle Charafe-Jauffret
Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
Int J Oncol 23:97-103. 2003..These results show that UCNT morphologically resembling HL share also some specific phenotypical and molecular features with HL, and might deserve to be isolated as a particular UCNT subtype...- Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancerEmmanuelle Charafe-Jauffret
Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
Clin Cancer Res 16:45-55. 2010..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer... - Breast cancer stem cells: tools and models to rely onEmmanuelle Charafe-Jauffret
Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Marseille, France
BMC Cancer 9:202. 2009..In this review, we survey tools and markers available or promising to identify breast CSCs. We review the main models used to study breast CSCs and how they challenge the CSC hypothesis... - Cancer stem cells in breast: current opinion and future challengesEmmanuelle Charafe-Jauffret
Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
Pathobiology 75:75-84. 2008..Following this approach, new molecules are currently in development. Focusing on the cross-talk between stem cells and their microenvironment is also a promising way to explore how to better target cancer stem cells and be curative... - Vertebral metastases from pineoblastomaE Charafe-Jauffret
Department of Pathology, Centre Régional de Lutte contre le Cancer Institut Paoli Calmettes, Marseille, France
Arch Pathol Lab Med 125:939-43. 2001..These uncommon cases are discussed with reference to the literature on extraneural metastases that originate from neuroepithelial tumors of the central nervous system... - [Inflammatory breast carcinoma: towards molecular characterization?]Emmanuelle Charafe-Jauffret
Département de biopathologie, Institut Paoli Calmettes, Marseille
Ann Pathol 23:564-9. 2003..It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC... - Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotypeStephane Garcia
Department of Pathology, Centre Hospitalo Universitaire Nord, 13916 Marseille, France
Hum Pathol 38:830-41. 2007.... - [Towards an integrated cellular and molecular: definition of breast cancers]Emmanuelle Charafe Jauffret
UMR 599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancérologie de Marseille et Université de la Méditerranée, 27, boulevard Lei Roure, 13009 Marseille, France
Med Sci (Paris) 23:626-32. 2007..These combined studies allow a new integrated cellular and molecular definition of breast cancers and a conceptual basis that will help the management of the disease... - Inflammatory breast cancers in Tunisia and France show similar immunophenotypesEmmanuelle Charafe Jauffret
Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, IFR137 Marseille, France
Breast 16:352-8. 2007..It is thought that IBC occurs with a high frequency in Tunisia. The aim of this study is to evaluate this signature on a Tunisian series... - Identification and validation of an ERBB2 gene expression signature in breast cancersFrancois Bertucci
Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
Oncogene 23:2564-75. 2004..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples... - Integrated profiling of basal and luminal breast cancersJosé Adélaïde
Marseille Cancer Research Center, Department of Molecular Oncology, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, Marseille, France
Cancer Res 67:11565-75. 2007..Finally, among 10p candidate oncogenes associated with basal subtype, we validated CDC123/C10orf7 protein as a basal marker... - Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesisStephane Garcia
Department of Pathology, Centre Hospitalo Universitaire, Hopital Nord, Marseille, France
Int J Oncol 31:49-58. 2007.... - Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopyOlivier Ramuz
INSERM U119, Service d Anatomie et Cytologie Pathologiques, Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, IFR 57 and Université de la Méditerranée, Marseille, France
Int J Exp Pathol 84:75-81. 2003..These results provide new perspectives about the subcellular compartmentation and traffic of caspases during the apoptotic process... 
How different are luminal A and basal breast cancers?Francois Bertucci
Département d Oncologie Moléculaire, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
Int J Cancer 124:1338-48. 2009....- Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancerChristophe Ginestier
Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
Int J Cancer 107:854-62. 2003..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment... - Defining the molecular biology of inflammatory breast cancerEmmanuelle Charafe-Jauffret
Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, IFR137, 232 Boulevard Sainte Marguerite, Marseille Cedex 09, France
Semin Oncol 35:41-50. 2008..The aim of this review is to present and discuss what is known about the biology of this particularly aggressive form of breast cancer and to discuss how this knowledge could improve its management... - Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulatorsNathalie Conte
Département d Oncologie Moléculaire, U119 INSERM, 27 Bd Lei Roure, 13009, Marseille, France
Oncogene 21:5619-30. 2002..We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes... - Typical medullary breast carcinomas have a basal/myoepithelial phenotypeJocelyne Jacquemier
Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
J Pathol 207:260-8. 2005..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)... - [Small but high throughput: how "tissue-microarrays" became a favorite tool for pathologists and scientists]Jocelyne Jacquemier
Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13273 Marseille Cedex 9, France
Ann Pathol 23:623-32. 2003..This Article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research... - Moesin expression is a marker of basal breast carcinomasEmmanuelle Charafe-Jauffret
Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
Int J Cancer 121:1779-85. 2007..014). In multivariate analysis, Moesin expression was nearly an independent prognostic marker of poor outcome as shown by Cox proportional hazard model in patients without lymph node metastasis (p = 0.052, HR = 2.38, CI 95[0.99-5.69])... - [Radiotherapy in adult glioblastomas]P Y Bondiau
Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06100 Nice, France
Neurochirurgie 56:486-90. 2010..After a review of the physical and biological bases of ionizing radiation, we present the techniques, results, side effects, and results of irradiation of glioblastomas... - ETV6 gene rearrangements in invasive breast carcinomaAnne Letessier
Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
Genes Chromosomes Cancer 44:103-8. 2005..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement... - Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT geneCornel Popovici
Département d Oncologie Moléculaire, Institut Paoli Calmettes, Marseille, France
Genes Chromosomes Cancer 35:204-18. 2002..Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p14;p11) reciprocal translocation was found... - Chromosome arm 8p and cancer: a fragile hypothesisDaniel Birnbaum
Department of Molecular Oncology, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
Lancet Oncol 4:639-42. 2003..We have found that chromosome breaks disrupt the NRG1 gene at 8p12 in breast and pancreatic cancers. We hypothesise that alteration of the NRG1 gene could occur through breakage at a non-common fragile site... - Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypesAnthony Goncalves
Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
Mol Cell Proteomics 7:1420-33. 2008..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values... - Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosisPascal Finetti
UMR599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
Cancer Res 68:767-76. 2008..The identification of luminal A cases of poor prognosis should help select appropriate treatment, whereas the identification of a relevant kinase set provides potential targets... - Basal and luminal breast cancers: basic or luminous? (review)Daniel Birnbaum
Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
Int J Oncol 25:249-58. 2004..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...